deferoxamine has been researched along with Leukemia, Myeloid, Acute in 12 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFO) is an iron chelator that is known to inhibit acute non-lymphocytic leukemia cells in vitro." | 5.28 | Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. ( Arena, VC; Blatt, J; Boegel, F; Hedlund, BE; Shadduck, RK, 1991) |
| "Deferoxamine (DFO) is an iron chelator that is known to inhibit acute non-lymphocytic leukemia cells in vitro." | 1.28 | Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. ( Arena, VC; Blatt, J; Boegel, F; Hedlund, BE; Shadduck, RK, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Batsivari, A | 1 |
| Grey, W | 1 |
| Bonnet, D | 1 |
| Merkel, DG | 1 |
| Nagler, A | 1 |
| Rose, C | 1 |
| Brechignac, S | 1 |
| Vassilief, D | 1 |
| Pascal, L | 1 |
| Stamatoullas, A | 1 |
| Guerci, A | 1 |
| Larbaa, D | 1 |
| Dreyfus, F | 1 |
| Beyne-Rauzy, O | 1 |
| Chaury, MP | 1 |
| Roy, L | 1 |
| Cheze, S | 1 |
| Morel, P | 1 |
| Fenaux, P | 1 |
| Armand, P | 1 |
| Sainvil, MM | 1 |
| Kim, HT | 1 |
| Rhodes, J | 1 |
| Cutler, C | 1 |
| Ho, VT | 1 |
| Koreth, J | 1 |
| Alyea, EP | 1 |
| Neufeld, EJ | 1 |
| Kwong, RY | 1 |
| Soiffer, RJ | 1 |
| Antin, JH | 1 |
| Schmidt, D | 1 |
| Finke, J | 1 |
| Bridges, KR | 1 |
| Cudkowicz, A | 1 |
| Mattia, E | 1 |
| Rao, K | 1 |
| Shapiro, DS | 1 |
| Sussman, HH | 1 |
| Klausner, RD | 1 |
| Weiss, G | 1 |
| Goossen, B | 1 |
| Doppler, W | 1 |
| Fuchs, D | 1 |
| Pantopoulos, K | 1 |
| Werner-Felmayer, G | 1 |
| Grünewald, K | 1 |
| Wachter, H | 1 |
| Hentze, MW | 1 |
| Ammon, A | 1 |
| Rumpf, KW | 1 |
| Hommerich, CP | 1 |
| Behrens-Baumann, W | 1 |
| Rüchel, R | 1 |
| Blatt, J | 1 |
| Boegel, F | 1 |
| Hedlund, BE | 1 |
| Arena, VC | 1 |
| Shadduck, RK | 1 |
| Kaplinsky, C | 1 |
| Estrov, Z | 1 |
| Freedman, MH | 1 |
| Gelfand, EW | 1 |
| Cohen, A | 2 |
| Barankiewicz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload[NCT00658411] | 5 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Closed due to slow patient accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Survival information for the 5 patients who were treated with deferoxamine was collected. This information was used to determine transplant-related mortality, relapse, disease-free and overall survival. (NCT00658411)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Transplant-Related Mortality (Deferoxamine) | 0 |
| Relapse (Deferoxamine) | 0 |
| Disease-Free Survival (Deferoxamine) | 5 |
| Overall Survival (Deferoxamine) | 0 |
"All patients meeting the criteria for Severe iron overload as defined by BOTH:~ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades defined by the CTCAE Version 3). The number of participants with grade 3 or higher toxicities were measured and used to determine the safety of chelation therapy." (NCT00658411)
Timeframe: Baseline , 6 month, 1 year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Baseline | 6 month | 1 year | |
| Deferoxamine | 5 | 0 | 0 |
2 reviews available for deferoxamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Cell Communication; Cell Hypoxia; Deferoxamine; Disease Progression; | 2021 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def | 2014 |
1 trial available for deferoxamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
Topics: Adult; Chelation Therapy; Deferoxamine; Drug Monitoring; Early Termination of Clinical Trials; Feasi | 2013 |
9 other studies available for deferoxamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Topics: Aged; Aged, 80 and over; Chelation Therapy; Comorbidity; Deferoxamine; Disease Progression; Female; | 2010 |
[Bull's-Eye Maculopathy with Deferoxamine Treatment].
Topics: Aged; Anemia; Deferoxamine; Electroretinography; Erythrocyte Transfusion; Ferritins; Fluorescein Ang | 2004 |
Effect of iron chelators on the transferrin receptor in K562 cells.
Topics: Apoproteins; Cell Line; Cell Membrane; Deferoxamine; Humans; Iron; Iron Chelating Agents; Kinetics; | 1984 |
Biosynthetic regulation of the human transferrin receptor by desferrioxamine in K562 cells.
Topics: Animals; Cell Line; Deferoxamine; Humans; Kinetics; Leukemia, Myeloid, Acute; Poly A; Protein Biosyn | 1984 |
Stimulation of IRE-BP activity of IRF by tetrahydrobiopterin and cytokine dependent induction of nitric oxide synthase.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Biopterins; Cell Line; Chloramphenicol O-Acetyltransf | 1994 |
[Rhinocerebral mucormycosis during deferoxamine therapy].
Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human | 1992 |
Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine.
Topics: Animals; Deferoxamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Injec | 1991 |
Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.
Topics: Antigens, Surface; Benzamides; Cell Cycle; Cell Differentiation; Deferoxamine; DNA Repair; DNA, Neop | 1987 |
Impairment of nucleotide metabolism by iron-chelating deferoxamine.
Topics: Cell Division; Cell Line; Deferoxamine; Depression, Chemical; Humans; Iron; Leukemia, Myeloid, Acute | 1987 |